Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients

Pituitary

Volumn 14, Issue 3, 2011, Pages 253-258

  Neggers, Sebastian J C M M ^a   De Herder, Wouter W ^a   Feelders, Richard A ^a   Van Der Lely, A J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acromegaly; Acromegaly treatment; Combined treatment; Pegvisomant; Pituitary tumor; Somatostatin analogs

Indexed keywords

ANGIOPEPTIN; GLIBENCLAMIDE; GLUCOSE; GROWTH HORMONE; INSULIN GLARGINE; METFORMIN; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; CANCER INVASION; CASE REPORT; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GIGANTISM; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PRIORITY JOURNAL; SIDE EFFECT; TRANSSPHENOIDAL SURGERY; TUMOR VOLUME;

ACROMEGALY; ADULT; DRUG ADMINISTRATION SCHEDULE; HUMAN GROWTH HORMONE; HUMANS; MALE; PITUITARY NEOPLASMS; SOMATOSTATIN;

EID: 80053921557     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-010-0289-5     Document Type: Article

References (27)

1. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ (2005) Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365(9471):1644-1646 (Pubitemid 40693415)
2. Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ (2009) Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 160(4):529-533
3. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ (2007) Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 92(12):4598-4601 (Pubitemid 350223432)
4. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358(9295): 1754-1759 (Pubitemid 33152999)
5. Hodish I, Barkan A, Medscape (2008) Long-term effects of pegvisomant in patients with acromegaly. Nat clin pract 4(6):324-332 (Pubitemid 351733473)
6. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP (2008) Mortality in acromegaly: a meta-analysis. J clin Endocrinol Metab 93(1):61-67
7. Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159(2):89-95
8. Elmlinger MW, Kuhnel W, Weber MM, Ranke MB (2004) Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 42(6):654-664 (Pubitemid 38979144)
9. Neggers SJ, van der Lely AJ (2009) Somatostatin analog and pegvisomant combination therapy for acromegaly. Nat Rev Endocrinol 5(10):546-552
10. Trainer PJ, Ezzat S, D'Souza GA, Layton G, Strasburger CJ (2009) A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endo-crinol 71(4):549-557
11. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO, Hagen C, Orskov H (2005) Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90(10):5627-5631 (Pubitemid 41415468)
12. Leung KC, Doyle N, Ballesteros M, Waters MJ, Ho KK (2000) Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J Clin Endocrinol Metab 85(12):4712-4720 (Pubitemid 32157657)
13. Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, Webb SM, van der Lely AJ (2008) Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 93(10):3853-3859
14. Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S (2004) Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Investig 114(3):349-356 (Pubitemid 39071607)
15. Shishko PI, Dreval AV, Abugova IA, Zajarny IU, Goncharov VC (1994) Insulin-like growth factors and binding proteins in patients with recent-onset type 1 (insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion. Diabetes Res Clin Pract 25(1):1-12 (Pubitemid 24288040)
16. Wurzburger MI, Prelevic GM, Sonksen PH, Balint-Peric LA, Wheeler M (1993) The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes. J Clin Endocrinol Metab 77(1):267-272 (Pubitemid 23206814)
17. van der Hoek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, Bruns C, Poon KW, Lewis I, Weckbecker G, Krahnke T, Hofland LJ, Lamberts SW (2004) A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 89(2):638-645 (Pubitemid 38269871)
18. Strowski MZ, Blake AD (2008) Function and expression of somatostatin receptors of the endocrine pancreas. Mol Cell Endocrinol 286(1-2):169-179
19. Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Investigation 119(11):3189-3202. doi:10.1172/JCI39375
20. Thorner MO, Perryman RL, Cronin MJ, Rogol AD, Draznin M, Johanson A, Vale W, Horvath E, Kovacs K (1982) Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. J Clin Investigation 70(5):965-977 (Pubitemid 13254920)
21. Vallar L, Spada A, Giannattasio G (1987) Altered Gs and aden-ylate cyclase activity in human GH-secreting pituitary adenomas. Nature 330(6148):566-568 (Pubitemid 17164352)
22. Buhk JH, Jung S, Psychogios MN, Goricke S, Hartz S, SchulzHeise S, Klingebiel R, Forsting M, Bruckmann H, Dorfler A, Jordan M, Buchfelder M, Knauth M (2010) Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab 95(2):552-558. doi:10.1210/jc.2009-1239
23. Trainer PJ (2009) ACROSTUDY: the first 5 years. Eur J Endo-crinol 161(Suppl 1):S19-24. doi:10.1530/EJE-09-0322
24. Parkinson C, Drake WM, Roberts ME, Meeran K, Besser GM, Trainer PJ (2002) A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab 87(4):1797-1804 (Pubitemid 34615271)
25. Castinetti F, Morange I, Dufour H, Regis J, Brue T (2009) Radiotherapy and radiosurgery in acromegaly. Pituitary 12(1): 3-10. doi:10.1007/s11102-007- 0078-y
26. van der Klaauw AA, Biermasz NR, Hoftijzer HC, Pereira AM, Romijn JA (2008) Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly. Clin Endocrinol 69(1):123-128 (Pubitemid 351847272)
27. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS (2004) Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89(4):1613-1617 (Pubitemid 38507910)